adbone® synthetic bone grafts are built on over 15 years of biomaterial research — engineered to replicate the microarchitecture of human bone with reproducible, measurable performance that biological grafts cannot guarantee.
Natural bone is approximately 70% mineral — predominantly calcium phosphate in the form of hydroxyapatite. adbone® replicates this chemistry through a patented manufacturing process that controls phase composition, pore geometry, and interconnectivity at the microscale.
Measured across the three parameters most predictive of successful bone regeneration. Data sourced from Medbone product specifications and published biomaterial benchmarks.
Higher porosity = greater surface area for cell colonisation. A 25-point difference is clinically significant for 3D bone ingrowth.
Pores ≥100μm are required for vascularisation. adbone® exceeds this threshold by 4× — enabling capillary penetration deep into the graft core.
6× greater compressive strength without sacrificing porosity — the result of Medbone's patented sintering and microarchitecture design.
Bone graft materials are classified by biological origin. adbone® occupies the alloplastic (synthetic) category — offering the predictability, safety, and unlimited availability that biological grafts cannot guarantee.
Porosity is not merely a structural feature — it is the primary driver of biological integration. An interconnected pore network allows cells to migrate, blood vessels to form, and new bone to grow in three dimensions simultaneously. Without it, regeneration remains surface-level.
The interconnected porous architecture of adbone® acts as a three-dimensional template, physically guiding osteoblast migration, proliferation, and matrix deposition across the entire graft volume — not merely on its outer surface. Macropores of 100–400μm represent the critical size range for vascular and bone tissue ingrowth, and adbone® achieves this throughout its full structural depth.
New blood vessel formation is essential for sustained bone regeneration. adbone®'s interconnected pore channels allow capillaries to penetrate deep into the graft core, continuously supplying oxygen, nutrients, and growth factors. Without deep vascularisation, even osteoconductive scaffolds fail at their centre — a limitation adbone®'s architecture is specifically designed to overcome.
adbone® degrades via osteoclast activity at a rate matched to new bone deposition. Pure β-TCP degrades relatively quickly, making adbone® TCP the choice where full resorption is the goal. In BCP formulations, the HAp phase degrades more slowly, providing sustained mechanical support through the extended healing phase — the key clinical advantage of staged biphasic resorption.
The hydrophilic surface of adbone® draws blood rapidly into the pore network upon implantation, delivering platelets, growth factors (BMP-2, TGF-β, PDGF), and mesenchymal stem cells directly to the scaffold interior — effectively augmenting osteoinductive potential without requiring additional biologics. Surgeons may also mix adbone® with bone marrow aspirate to further enhance performance in complex defects.
Medbone operates under a certified Quality Management System and holds CE marking across the full adbone® range. Every batch is traceable, reproducible, and manufactured under strict GMP controls — ensuring clinicians receive consistent performance with every implantation.
Tarsal Medical provides clinical support, product samples, and full technical documentation across South Africa.